Leinal polypeptide promotes NK cells to suppress PCa survival in�vitro

Abstract

As an important component in the innate immune system, natural killer (NK) cells have been demonstrated to be clinically associated with prostate cancer (PCa) progression and castration resistance. Therefore, the development of novel agents that may enhance the cytotoxicity of NK cells possesses promising therapeutic applications. In the present study, leinal polypeptide (LP) solution was supplemented into a co-culture system of NK and PCa cells, as it was previously demonstrated that LP are able to activate NK cells, which kill PCa cells based on an MTT cell viability assay. Mechanistic dissection demonstrated that LP enhanced androgen receptor degradation, which resulted in an upregulation of MHC class I polypeptide-related sequence A (MICA) and MICB. In turn, the induced expression of MICA and MICB was able to further trigger NK cell activation, forming a positive loop between NK cells and PCa cells in the presence of LP solution.

The effectiveness and safety of lienal polypeptide combined with chemotherapy or chemoradiotherapy for non-small cell lung cancer patients in real world

“…To reveal this mechanism, an in vitro experiment was carried out and showed that LP solution activated NK cell through androgen receptor and major histocompatibility complex class I polypeptide-related sequence A/B pathway. [ 14 ] In vitro experiments also showed that LP worked well together with cyclophosphamide and significantly reduced the tumor sizes of Lewis lung carcinoma-bearing mice. Furthermore, LP was also found to improve the immune system through phagocytosis-related pathway.…”